Health Care·Pharmaceuticals·$9.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | -6.85% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.78 | N/A | -6.85% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about the company's future, emphasizing their commitment to advancing their pipeline. They acknowledged the EPS miss but highlighted ongoing strategic initiatives.
We are focused on advancing our pipeline and are excited about our future prospects.
Despite the EPS miss, we remain committed to our strategic goals.
The earnings report reflects some challenges for Axovant Gene Therapies, particularly with the EPS miss. However, the stock rose by 2.73%, indicating that investors may be optimistic about the company's future plans and pipeline developments. The lack of revenue data and guidance leaves some uncertainty, but management's positive tone may have reassured investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BUILDERS FIRSTSOURCE
Feb 26, 2021